Budget Impact of Alteplase In Treatment of Acute Ischemic Stroke In Turkey

Cerebrovascular diseases are the sixth cause of total DALYs in Turkey and the Turkish Social Security Institution (SSI) faces a challenge on reimbursement decisions for treatment. Alteplase is a recombinant human tissue plasminogen activator indicated for treatment of acute ischemic stroke (AIS). Clinical trials have proved efficacy in reducing 90-day disability measured by the Modified Rankin Score (mRS) if administered within 4,5 hours of onset of symptoms. The agent is used as an addition to Standard of Care (SoC).

Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Tatar, A Şentürk, E Tetik, L Yıldız, J Cheynel Source Type: research